Healthcare Services

Global Eosinophilic Asthma Market Analysis for 2026–2030 with Strategic Forecast Insights for Businesses

April 1, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Eosinophilic Asthma Market Projected To Become By 2030 Based On Its 2026 Valuation?

The eosinophilic asthma market has experienced swift expansion recently. It is set to expand from $3.16 billion in 2025 to $3.71 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.4%. This historical growth can be ascribed to a poor response to inhaled steroids, an increase in asthma prevalence, the identification of eosinophil biomarkers, a rise in hospital asthma admissions, and the burden of chronic respiratory diseases.

The eosinophilic asthma market size is anticipated to undergo significant expansion in the coming years. Its value is projected to reach $6.92 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.9%. This growth throughout the forecast period is attributable to the advancement of precision asthma treatment, the enlargement of the biologic drug pipeline, biomarker-based diagnosis, personalized respiratory care, and the proliferation of specialty clinics. Key trends during this period involve the increasing adoption of biologic therapies, an elevated focus on severe asthma phenotypes, a rising demand for targeted immunotherapy, the expansion of specialized respiratory clinics, and an emphasis on reducing exacerbation rates.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Eosinophilic Asthma Market?

The anticipated expansion of the eosinophilic asthma market is linked to an increase in smoking habits. These habits denote consistent patterns or actions related to tobacco product consumption, encompassing the frequency, setting, and duration of smoking, frequently shaped by psychological, social, and environmental influences. The surge in smoking behaviors stems from elements like elevated stress, focused promotional efforts from tobacco firms, insufficient knowledge of associated health dangers, and the cultural normalization of smoking in specific communities. Treating eosinophilic asthma aids in diminishing airway inflammation and enhancing lung performance, potentially fostering smoking cessation by easing the breathing problems that frequently prompt individuals to persist with smoking. For example, data from November 2025, supplied by the Office for National Statistics, a UK-based government agency, indicated that the proportion of women in Great Britain reporting e-cigarette use rose from 8.5% in 2023 to 10.0% in 2024. Additionally, daily e-cigarette consumption was most prevalent among those aged 25 to 34 years and 35 to 49 years in Great Britain, at 9.3% and 9.5% respectively, showing an uptick in both age demographics since 2023. Consequently, the escalating rates of smoking are propelling the eosinophilic asthma market.

What Segment Groups Are Identified Within The Eosinophilic Asthma Market?

The eosinophilic asthma market covered in this report is segmented –

1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma

2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma

2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma

What Trends Are Affecting The Expansion Of The Eosinophilic Asthma Market?

Leading companies in the eosinophilic asthma market are developing innovative medications designed to target specific immune pathways, reduce inflammation, and enhance patient outcomes through personalized treatment options. A monoclonal antibody is a synthetic molecule created in laboratories that can mimic the immune system’s capacity to combat harmful pathogens such as viruses and bacteria. These are generated through a process involving the fusion of a particular antibody-producing cell with a cancer cell, allowing for the mass production of identical antibodies. For instance, in August 2024, AstraZeneca plc, a UK-based biopharmaceutical company, announced that Fasenra received approval from China’s National Medical Products Association, a China-based government agency, for the management of severe eosinophilic asthma. It is specifically prescribed for patients with severe eosinophilic asthma, a condition defined by elevated eosinophil levels that can result in inflammation and worsening asthma symptoms. Fasenra is a monoclonal antibody that targets and depletes eosinophils through a unique mechanism. It enhances the immune system’s capability by binding to the IL-5 receptor on eosinophils to decrease eosinophil levels in the blood and tissues. The dosing regimen includes an initial loading phase followed by maintenance doses. Patients typically receive injections every four weeks for the first three doses, and thereafter every eight weeks.

Which Companies Hold Significant Positions In The Eosinophilic Asthma Market?

Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, Bayer AG, Eli Lilly and Company, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Cipla Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Kirin Co. Ltd., UCB S.A., 4D Pharma plc, MorphoSys AG, Avalo Therapeutics Inc.

Read the full eosinophilic asthma market report here:

https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

Which Regions Are Projected To Dominate The Eosinophilic Asthma Market In The Coming Years?

North America was the largest region in the eosinophilic asthma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Eosinophilic Asthma Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21184&type=smp

Browse Through More Reports Similar to the Global Eosinophilic Asthma Market 2026, By The Business Research Company

Noise Vibration Harshness Testing Global Market Report

https://www.thebusinessresearchcompany.com/report/noise-vibration-harshness-testing-global-market-report

Cannabis Testing Global Market Report

https://www.thebusinessresearchcompany.com/report/cannabis-testing-global-market-report

Bioanalytical Testing Services Global Market Report

https://www.thebusinessresearchcompany.com/report/bioanalytical-testing-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795